Home
>
US Stocks
>
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
EYPT

EyePoint Pharmaceuticals Inc

$11.4915.71%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
11.42
Today Low/High
11.14 / 11.54
52 Week Low/High
$3.51 / $15.06
Market Cap
$290M

Company Details

EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.
Organisation
EyePoint Pharmaceuticals Inc
Employees
100
Industry
Health Technology

Discover more

Frequently Asked Questions

What is EyePoint Pharmaceuticals Inc share price today

Can Indians buy EyePoint Pharmaceuticals Inc shares?

How can I buy EyePoint Pharmaceuticals Inc shares from India?

Can Fractional shares of EyePoint Pharmaceuticals Inc be purchased?

What are the documents required to start investing in EyePoint Pharmaceuticals Inc stocks?

We are a SEBI registered investement advisor